首页> 外文期刊>Journal of Korean medical science >A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
【24h】

A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.

机译:用人源化抗白介素6受体抗体托珠单抗成功治疗了多发性患有肺部病变的Castleman病。

获取原文
获取原文并翻译 | 示例
           

摘要

This report presents the case of a patient demonstrating multicentric Castleman's disease (MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor antibody, tocilizumab in combination with corticosteroid and tacrolimus. A 43-yr-old female with abnormal shadows on a chest X-ray was referred to the hospital for further examination. She was diagnosed as having MCD based on the characteristic pathology of inguinal lymph node, lung lesions, laboratory data, and undifferentiated arthritis. Corticosteroid and rituximab therapy did not fully ameliorate the symptoms; thus, the therapeutic regimen was changed to include tocilizumab, oral corticosteroid and tacrolimus. This regimen resulted in clinical remission and the dose of tocilizumab and corticosteroid could be tapered. Tocilizumab in combination with corticosteroid and tacrolimus may therefore be a beneficial treatment regimen for lung lesions associated with MCD.
机译:该报告介绍了一个病人,该病人表现出肺损伤的多中心Castleman病(MCD),已成功用抗白介素6受体抗体,托珠单抗联合皮质类固醇和他克莫司治疗。一名43岁的女性,胸部X光片上有异常阴影,被转诊到医院接受进一步检查。根据腹股沟淋巴结的特征性病理,肺部病变,实验室数据和未分化的关节炎,她被诊断为患有MCD。皮质类固醇和利妥昔单抗治疗不能完全缓解症状。因此,治疗方案已更改为包括托珠单抗,口服皮质类固醇和他克莫司。该方案导致临床缓解,托珠单抗和皮质类固醇的剂量可以逐渐减少。因此,Tocilizumab联合皮质类固醇和他克莫司可能是与MCD相关的肺部病变的有益治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号